Bearing Point Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bearing Point Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.94M	Buy	24,906 +1,434	+6%	+$194K	0.53%	61
2026 Q1	$3M	Buy	23,472 +2,120	+10%	+$265K	0.47%	63
2025 Q4	$2.6M	Buy	21,352 +4,831	+29%	+$554K	0.41%	67
2025 Q3	$1.66M	Buy	16,521 +640	+4%	+$57.6K	0.28%	74
2025 Q2	$1.32M	Sell	15,881 -43,274	-73%	-$3.45M	0.24%	77
2025 Q1	$4.8M	Buy	59,155 +1,131	+2%	+$101K	1.02%	38
2024 Q4	$5.23M	Buy	+58,024	New	+$5.62M	1.09%	34

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Bearing Point Capital's XBI Position: Q2 2026 in Review

Bearing Point Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 6.1% in Q2 2026, buying an estimated $194K and bringing the position to 24,906 shares worth $3.94M. The position accounts for 0.53% of the portfolio, ranked #61.

Bearing Point Capital first reported a position in XBI in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.23M in Q4 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Bearing Point Capital held 24,906 shares of State Street SPDR S&P Biotech ETF worth $3.94M as of Q2 2026.
Bearing Point Capital bought 1,434 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $194K.
State Street SPDR S&P Biotech ETF made up 0.53% of Bearing Point Capital's portfolio in Q2 2026, its #61 holding.
Bearing Point Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 7 quarters since.
Bearing Point Capital's State Street SPDR S&P Biotech ETF position peaked at $5.23M in Q4 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Bearing Point Capital's 13F filing for Q2 2026, filed 11 Aug 2026.